Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-MTAB-7453

ABSTRACT: RNA-seq of the human melanoma cell-line A375P treated with the BRAF inhibitor PLX4720 and a DMSO control

PROVIDER: E-MTAB-7453 | ExpressionAtlas | 2025-01-23

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-MTAB-7453-analysis-methods.tsv	Tabular
	E-MTAB-7453-analytics.tsv	Tabular
	E-MTAB-7453-atlasExperimentSummary.Rdata	Rdata
	E-MTAB-7453-configuration.xml	Xml
	E-MTAB-7453-g2_g1-mvaPlot.png	Other

Items per page:

1 - 5 of 22

Similar Datasets

RNA-seq of the human melanoma cell-line A375P treated with the BRAF inhibitor PLX4720 and a DMSO control

Project description:RNA-seq of the human melanoma cell-line A375P treated with the BRAF inhibitor PLX4720 and a DMSO control

| PRJEB30062 | ENA

RNA-seq of human melanoma cancer cell line A375 treated with BET inhibitor JQ1 against untreated control

Project description:RNA-seq of human melanoma cancer cell line A375 treated with BET inhibitor JQ1 against untreated control

| PRJEB36126 | ENA

RNA-seq of human melanoma cell line A375m2 treated with SB202190 OR BIRB796 against DMSO-treated controls

Project description:RNA-seq of human melanoma cell line A375m2 treated with SB202190 OR BIRB796 against DMSO-treated controls

| PRJEB39122 | ENA

The mitochondrial protease LonP1 promotes proteasome inhibitor resistance in multiple myeloma.

Project description:Purpose: We report the NGS-derived transcriptome profiling (paired-end RNA-seq) following proteasome inhibition in the multiple myeloma cell line MM.1S. Methods: MM.1S cells were treated for six hours with the synthetic proteasome inhibitor lactacystin or clinically-approved proteasome inhibitor bortezomib and RNA expression changes were quantified and compared to DMSO control-treated cells by RNA-sequencing.

2021-03-06 | GSE166122 | GEO

Gene expression in Vemurafenib-treated A375 and A2058 melanoma cell lines

Project description:Human melanoma cell line A375 and A2058 were incubated with DMSO (control group) or Vemurafenib (1 μM in DMSO) for 72 hours. Total RNA was isolated with Qiagen RNA isolation kit; 1.5 μg of total RNA was used as template for cDNA synthesis.

2015-12-02 | GSE52882 | GEO

Novel azetidine-based Stat3 inhibitors induce misfolded protein response, endoplasmic reticulum stress and mitophagy, and inhibit breast tumor growth in vivo

Project description:To identify differentially expressed genes and pathways in human breast cancer cell line MDA-MB-231 cells that are treated with a novel Stat3 inhibitor or DMSO control.

2022-07-12 | GSE180123 | GEO

Proteasome inhibition silences oncogenic transcripts in multiple myeloma through HDAC3-mediated DNA condensation and gene relocation [RNA-seq]

Project description:Purpose: We report the NGS-derived transcriptome profiling (paired-end RNA-seq) following proteasome inhibition in the multiple myeloma cell line MM.1S. Methods: MM.1S cells were treated for six hours with the synthetic proteasome inhibitor lactacystin and RNA expression changes were quantified and compared to DMSO control-treated cells by RNA-sequencing.

2022-11-21 | GSE193300 | GEO

Effect of Cpd1 on melanoma proteome

Project description:Investigation of the time dependent effect of Cpd1 (small molecule interactor) on the proteome composition of melanoma WM3734 line by label-free quantification using mass spectrometry. The goal was to identify which protein abundances are increased upon treatment with Cpd1. Melanoma cell line WM3734 was treated with Cpd1 and with the control DMSO. Samples were taken at two time points, 24h and 72h.

2022-03-14 | PXD008757 | Pride

RNA-seq analysis of human pancreas cell line SU8686 treated with DOT1L inhibitor (SGC0946) or DMSO

Project description:RNA-seq analysis of human pancreas cell line SU8686 treated with DOT1L inhibitor (SGC0946) or DMSO

| PRJNA578266 | ENA

LPAR signaling activated in neural crest stem cells promotes melanoma cell growth, invasion and therapy resistance [HumanHT-12 V4.0]

Project description:LPAR1 (lysophosphatidic acid receptor 1) is identified in targeted siRNA screens which is required for the survival and maintenance of nueral crest stem cells (NCSC) as well as the growth and invasion of melanoma cells. To gain mechanistic insights into how LPAR signaling modulates melanoma cell growth, We conducted an Illumina genome-wide gene expression microarray experiment to profile melanoma cells treated with the autotaxin inhibitor, HA130. Melanoma cells treated with vehicle control,DMSO is included as a control.

2017-12-01 | GSE92764 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data